Skip to Main Content

Paper Details

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.
Cell
2907
2020
COVID-19, IL-6, SARS, SARS-, SARS-CoV-2, humanity, patients, type I and III interferons
Author NameAffiliation
Benjamin E Nilsson-PayantIcahn School of Medicine at Mount Sinai, USA Virus Engineering Center for Therapeutics and Research
David SachsIcahn School of Medicine at Mount Sinai
David SachsIcahn School of Medicine at Mount Sinai
Jean K LimIcahn School of Medicine at Mount Sinai
Randy A AlbrechtIcahn School of Medicine at Mount Sinai, USA Global Health and Emerging Pathogens Institute
Benjamin R tenOeverIcahn School of Medicine at Mount Sinai, USA Virus Engineering Center for Therapeutics and Research, USA Global Health and Emerging Pathogens Institute
  • 1 - 6

Datasets

Release 1.2